临床前CDMO研发筛选相关化合物如有产品调研服务, 请致函联系我们
客户展示
临床前CDMO研发化合物筛选
Treprostinil sodium
中文名称:曲前列尼尔钠
CAS号:289480-64-4
分子式: C23H33NaO5 分子量: 412.49
产品形式: sodium
研发状态: Active not recruiting
研发用途: Pulmonary Arterial Hypertension
研究机构: United Therapeutics
研发日期: July 5 2023
研发阶段: --
Treprostinil sodium (UT-15, Remodulin, Orenitram, Tyvaso, Trevyent) is a potent agonist of DP1, EP2 and IP receptors with Ki 4.4 nM, 3.6 nM and 32 nM, respectively.
Carbidopa
中文名称:卡别多巴
CAS号:28860-95-9
分子式: C10H14N2O4 分子量: 226.23
产品形式: free base
研发状态: Recruiting
研发用途: Depressive Disorder Major
研究机构: Charite University Berlin Germany; Prof. Dr. Stefan M. Gold; Prof. Dr. Soyoung Q Park; Dr. Ulrike Grittner; Motognosis GmbH
研发日期: July 26 2023
研发阶段: Not Applicable
Carbidopa is an aromatic-L-amino-acid decarboxylase inhibitor with an IC50 of 29 ± 2 μM.
Cediranib (AZD2171)
中文名称:西地尼布
CAS号:288383-20-0
分子式: C25H27FN4O3 分子量: 450.51
产品形式: free base
研发状态: Withdrawn
研发用途: Uveal Melanoma; Metastatic Cancer
研究机构: Grupo Español Multidisciplinar de Melanoma; MFAR
研发日期: May-20
研发阶段: Phase 2
Cediranib (AZD2171, NSC-732208) is a highly potent VEGFR(KDR) inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50 of 5 nM/≤3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3 in HUVEC cells. Cediranib (AZD2171) induces autophagic vacuole accumulation. Phase 3.
Oxcarbazepine
中文名称:奥卡西平
CAS号:28721-07-5
分子式: C15H12N2O2 分子量: 252.27
产品形式: free base
研发状态: Completed
研发用途: Multiple Sclerosis
研究机构: Queen Mary University of London; National Multiple Sclerosis Society; Novartis Pharmaceuticals; Barts & The London NHS Trust; University College London; Royal Free Hospital NHS Foundation Trust; Mid and South Essex NHS Foundation Trust; St George''s Healthcare NHS Trust; Barnet and Chase Farm Hospitals NHS Trust
研发日期: Oct-14
研发阶段: Phase 2
Oxcarbazepine (GP47680) inhibits the binding of [3H]BTX to sodium channels with IC50 of 160 μM and also inhibits the influx of 22Na+ into rat brain synaptosomes with IC50 about 100 μM.
Doramapimod (BIRB 796)
中文名称: 多马莫德
CAS号:285983-48-4
分子式: C31H37N5O3 分子量: 527.66
产品形式: free base
研发状态: Completed
研发用途: Healthy
研究机构: Boehringer Ingelheim
研发日期: Oct-02
研发阶段: Phase 1
Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with Kd of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.
Sorafenib (BAY 43-9006)
中文名称:索拉非尼
CAS号:284461-73-0
分子式: C21H16ClF3N4O3 分子量: 464.82
产品形式: Free Base
研发状态: Recruiting
研发用途: Pancreas Cancer
研究机构: HonorHealth Research Institute; Bayer; Genentech Inc.
研发日期: October 28 2021
研发阶段: Phase 2
Sorafenib (BAY 43-9006, NSC-724772) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
我们的宗旨: 净化, 简洁, 高效Purifying, concise, efficient !我们的口号: 减少中间商赚差价!
即日起可免费注册成为会员, 建立企业产品库, 免费上传产品目录, 企业介绍等. 让你的产品直接呈现给客户.
试运营阶段,所有广告业务5折优惠
分类广告投放
依据化学成分的不同, 针对不同的企业和产品, 我们提供分类产品广告投放.客户展示
优秀企业推荐
